Lynx1 Capital Management LP Has $70.05 Million Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Lynx1 Capital Management LP grew its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 40.3% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,185,191 shares of the company’s stock after purchasing an additional 1,488,371 shares during the quarter. Stoke Therapeutics makes up approximately 25.3% of Lynx1 Capital Management LP’s holdings, making the stock its 2nd biggest position. Lynx1 Capital Management LP owned about 0.10% of Stoke Therapeutics worth $70,052,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Nisa Investment Advisors LLC grew its holdings in Stoke Therapeutics by 53.2% during the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock valued at $40,000 after purchasing an additional 1,038 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Stoke Therapeutics by 5.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 31,431 shares of the company’s stock valued at $425,000 after acquiring an additional 1,642 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Stoke Therapeutics by 16.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after acquiring an additional 1,994 shares in the last quarter. Quest Partners LLC bought a new stake in Stoke Therapeutics during the 2nd quarter worth approximately $29,000. Finally, Los Angeles Capital Management LLC raised its stake in Stoke Therapeutics by 7.2% during the 2nd quarter. Los Angeles Capital Management LLC now owns 66,765 shares of the company’s stock worth $902,000 after acquiring an additional 4,508 shares during the period.

Stoke Therapeutics Stock Down 3.9 %

STOK opened at $12.26 on Friday. The stock’s 50 day moving average price is $14.39 and its 200-day moving average price is $13.27. Stoke Therapeutics, Inc. has a one year low of $3.35 and a one year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.11. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%. The company had revenue of $4.83 million for the quarter, compared to the consensus estimate of $3.33 million. Equities analysts forecast that Stoke Therapeutics, Inc. will post -2.18 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on STOK shares. Wedbush reissued an “outperform” rating and issued a $17.00 price objective on shares of Stoke Therapeutics in a research note on Thursday, July 11th. HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday, September 11th. Finally, Needham & Company LLC reissued a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Stoke Therapeutics has an average rating of “Moderate Buy” and an average target price of $21.40.

Insider Activity at Stoke Therapeutics

In other news, insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $13.75, for a total value of $137,500.00. Following the completion of the sale, the insider now owns 2,485 shares of the company’s stock, valued at approximately $34,168.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Barry Ticho sold 10,000 shares of Stoke Therapeutics stock in a transaction on Monday, July 1st. The stock was sold at an average price of $13.75, for a total value of $137,500.00. Following the transaction, the insider now directly owns 2,485 shares in the company, valued at approximately $34,168.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Skorpios Trust sold 1,937,500 shares of the company’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the sale, the insider now owns 8,906,181 shares of the company’s stock, valued at $125,131,843.05. The disclosure for this sale can be found here. 11.30% of the stock is currently owned by company insiders.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.